Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in pediatric patients with persistent fever and neutropenia
2014-005021-13Phase 2
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in mycoses comparing Caspofungin arm with Liposomal amphotericin B arm (2 arms). Primary endpoint: Primary safety endpoint.
02
Drugs
caspofunginamphotericin b
03
Conditions
mycoses
Beyond the preview
Go deeper on 2014-005021-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005021-13.